Detalhe da pesquisa
1.
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Nature
; 595(7867): 432-437, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34135506
2.
Adjunctive Surgery Is Often Without Oncological Benefit at Time of Postchemotherapy Retroperitoneal Lymph Node Dissection.
J Urol
; 211(3): 426-435, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38085711
3.
Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial.
Int J Cancer
; 152(5): 854-864, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36121664
4.
Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets.
Br J Cancer
; 129(10): 1580-1589, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726478
5.
Quantum State Assignment Flows.
Entropy (Basel)
; 25(9)2023 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37761552
6.
A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial.
Int J Cancer
; 150(11): 1861-1869, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35076933
7.
Quality of life after robotic-assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP-01).
Prostate
; 82(8): 894-903, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35254665
8.
Postchemotherapy Residual Tumor Resection in Patients with Elevated Tumor Markers.
J Urol
; 207(3): 617-626, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34694152
9.
Value of T2 Mapping MRI for Prostate Cancer Detection and Classification.
J Magn Reson Imaging
; 56(2): 413-422, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35038203
10.
Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND).
World J Urol
; 40(2): 349-354, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34731264
11.
Late relapsing germ cell tumors with elevated tumor markers.
World J Urol
; 40(2): 363-371, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34518930
12.
Prognostic factors in patients with clinical stage I nonseminoma-beyond lymphovascular invasion: a systematic review.
World J Urol
; 40(12): 2879-2887, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35906286
13.
Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic review.
World J Urol
; 40(12): 2843-2852, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35037965
14.
How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.
World J Urol
; 40(12): 2863-2878, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35554637
15.
Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review.
World J Urol
; 40(12): 2889-2900, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36107211
16.
First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group.
World J Urol
; 40(12): 2853-2861, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35226138
17.
Therapy of clinical stage IIA and IIB seminoma: a systematic review.
World J Urol
; 40(12): 2829-2841, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779882
18.
Age-stratified outcomes after radical prostatectomy in a randomized setting (LAP-01): do younger patients have more to lose?
World J Urol
; 40(5): 1151-1158, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35124734
19.
Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility.
World J Urol
; 40(6): 1505-1512, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35279732
20.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(4): 525-537, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721560